Download PDF
Z Gastroenterol 2010; 48(4): 486-498
DOI: 10.1055/s-0029-1245278
Leitlinie

© Georg Thieme Verlag KG Stuttgart · New York

Histopathologische Diagnose der nicht alkoholischen und alkoholischen Fettlebererkrankung

Histopathological Diagnose of Non-alcoholic and Alcoholic Fatty Liver DiseaseA. Tannapfel1 , H. Denk2 , H.-P. Dienes3 , C. Langner2 , P. Schirmacher4 , M. Trauner5 , B. Flott-Rahmel1
  • 1Institut für Pathologie, Ruhr-Universität Bochum
  • 2Institut für Pathologie, Medizinische Universität Graz
  • 3Institut für Pathologie, Universität zu Köln
  • 4Pathologisches Institut, Universitätsklinikum Heidelberg
  • 5Klinische Abteilung für Gastroenterologie und Hepatologie, Medizinische Universität Graz
Further Information

Publication History

Manuskript eingetroffen: 21.12.2009

Manuskript akzeptiert: 10.2.2010

Publication Date:
29 March 2010 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Eine alkoholische (AFL) und eine nicht alkoholische Fettleber (NAFL) zeichnen sich durch eine Einlagerung von Lipiden in die Hepatozyten aus. Bei einer Beteiligung von > 5 % der Hepatozyten spricht man von „Verfettung”, bei > 50 % von einer „Fettleber”. Eine zusätzliche Entzündungsreaktion mit hepatozytärer Ballonierung führt zur alkoholischen (ASH) oder nicht alkoholischen (NASH) Steatohepatitis. Eine ASH bzw. NASH kann zur Fibrose oder Zirrhose führen. In der klinischen Praxis ist es bislang allein auf Basis nicht invasiver Tests nicht möglich, zwischen Steatose und Steatohepatitis zu unterscheiden. Eine Steatohepatitis liegt dann vor, wenn neben der Steatose gemischtzellige entzündliche Infiltrate in den Leberläppchen nachweisbar sind und zusätzlich eine Leberzellschädigung in Form einer Ballonierung vorliegt. Die Leberbiopsie ist der „Goldstandard” bei der Sicherung der Diagnose sowie der Bestimmung der entzündlichen Aktivität und möglichen Fibrose einer Fettlebererkrankung. Die Indikation zur Biopsie sollte den möglichen Informationsgewinn durch die Biopsie und seine Konsequenzen im Vergleich zu Aufwand und Komplikationsrate berücksichtigen und daher im klinischen Kontext gestellt werden.

Abstract

Alcoholic fatty liver (AFL) as well as non-alcoholic fatty liver (NAFL) are characterised by deposition of lipids into hepatocytes. The diagnosis of steatosis is made if lipid deposition exceeds 5 % of hepatocytes, in case of more than 50 % it is called ”fatty liver”. An additional inflammatory reaction, with ballooning of hepatocytes, leads to alcoholic steatohepatitis (ASH) or non-alcoholic steatohepatitis (NASH). Both ASH or NASH may lead to fibrosis or cirrhosis. To date in clinical practice it is not possible to differentiate between steatosis and steatohepatitis just on the basis of non-invasive tests. Steatohepatitis is present if, along with steatosis, both inflammatory infiltrates of mixed cells in the small liver lobules and liver cell injury in terms of ballooning can be detected. Liver biopsy represents the ”gold standard” for confirming the diagnosis and to determine inflammatory activity and potential fibrosis of fatty liver disease. Indications for biopsy should take into account the possible information and its consequences as compared to expense and complication rate and therefore should be assessed in the clinical context.

Schlüsselwörter

nicht alkoholische Steatohepatitis - alkoholische Steatohepatitis - Chemotherapie - kindliche NASH - Ballonierung - Fibrose - Zirrhose - Differenzialdiagnose - Scoring - Leberbiopsie

Key words

non-alcoholic steatohepatitis - alcoholic steatohepatitis - chemotherapy - NASH in children - ballooning - fibrosis - cirrhosis - differential diagnosis - scoring - liver biopsy

Literatur

  • 1 Adams L A, Talwalkar J A. Diagnostic evaluation of nonalcoholic fatty liver disease.  J Clin Gastroenterol. 2006;  40 34-38
    Google Scholar
  • 2 AGA . American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease.  Gastroenterology. 2002;  123 1702-1704
    Google Scholar
  • 3 Alfire M E, Treem W R. Nonalcoholic fatty liver disease.  Pediatr Ann. 2006;  35 290-299
    Google Scholar
  • 4 Aloia T, Sebagh M, Plasse M. et al . Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.  J Clin Oncol. 2006;  24 4983-4990
    Google Scholar
  • 5 Angulo P, Hui J M, Marchesini G. et al . The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.  Hepatology. 2007;  45 846-854
    Google Scholar
  • 6 Angulo P, Lindor K D. Non-alcoholic fatty liver disease.  J Gastroenterol Hepatol. 2002;  17 S186-S190
    Google Scholar
  • 7 Bacon B R, Farahvash M J, Janney C G. et al . Nonalcoholic steatohepatitis: an expanded clinical entity.  Gastroenterology. 1994;  107 1103-1109
    Google Scholar
  • 8 Baumann U. Die kindliche Fettlebererkrankung.  Dtsch Ärzteblatt. 2005;  102 A2634-A2639
    Google Scholar
  • 9 Bellentani S, Bedogni G, Miglioli L. et al . The epidemiology of fatty liver.  Eur J Gastroenterol Hepatol. 2004;  16 1087-1093
    Google Scholar
  • 10 Bonekamp S, Kamel I, Solga S. et al . Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately?.  J Hepatol. 2009;  50 17-35
    Google Scholar
  • 11 Brunt E M. Nonalcoholic steatohepatitis: definition and pathology.  Semin Liver Dis. 2001;  21 3-16
    Google Scholar
  • 12 Brunt E M. Alcoholic and nonalcoholic steatohepatitis.  Clin Liver Dis. 2002;  6 399-420
    Google Scholar
  • 13 Brunt E M. Pathology of fatty liver disease.  Mod Pathol. 2007;  20 S40-S48 (S 01)
    Google Scholar
  • 14 Brunt E M. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis.  Semin Diagn Pathol. 2005;  22 330-338
    Google Scholar
  • 15 Brunt E M. Pathology of nonalcoholic steatohepatitis.  Hepatol Res. 2005;  33 68-71
    Google Scholar
  • 16 Brunt E M, Janney C G, Di Bisceglie A M. et al . Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.  Am J Gastroenterol. 1999;  94 2467-2474
    Google Scholar
  • 17 Brunt E M, Neuschwander-Tetri B A, Oliver D. et al . Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens.  Hum Pathol. 2004;  35 1070-1082
    Google Scholar
  • 18 Brunt E M, Ramrakhiani S, Cordes B G. et al . Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease.  Mod Pathol. 2003;  16 49-56
    Google Scholar
  • 19 Brunt E M, Tiniakos D G. Pathology of steatohepatitis.  Best Pract Res Clin Gastroenterol. 2002;  16 691-707
    Google Scholar
  • 20 Brunt E M, Tiniakos D G. Pathological features of NASH.  Front Biosci. 2005;  10 1475-1484
    Google Scholar
  • 21 Burt A D, Mutton A, Day C P. Diagnosis and interpretation of steatosis and steatohepatitis.  Semin Diagn Pathol. 1998;  15 246-258
    Google Scholar
  • 22 Caldwell S H, Oelsner D H, Iezzoni J C. et al . Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.  Hepatology. 1999;  29 664-669
    Google Scholar
  • 23 Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography.  J Hepatol. 2008;  48 835-847
    Google Scholar
  • 24 Chitturi S, Abeygunasekera S, Farrell G C. et al . NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome.  Hepatology. 2002;  35 373-379
    Google Scholar
  • 25 Church T S, Kuk J L, Ross R. et al . Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease.  Gastroenterology. 2006;  130 2023-2030
    Google Scholar
  • 26 Cortez-Pinto H, Moura M C, Day C P. Non-alcoholic steatohepatitis: from cell biology to clinical practice.  J Hepatol. 2006;  44 197-208
    Google Scholar
  • 27 Dancygier de H. Pathogenese und Therapie der nichtalkoholischen Fettlebererkrankungen.  Dtsch Ärzteblatt. 2006;  103 A1301-A1307
    Google Scholar
  • 28 Day C P. Non-alcoholic fatty liver disease: current concepts and management strategies.  Clin Med. 2006;  6 19-25
    Google Scholar
  • 29 Day C P. Pathogenesis of steatohepatitis.  Best Pract Res Clin Gastroenterol. 2002;  16 663-678
    Google Scholar
  • 30 Day C P, James O F. Steatohepatitis: a tale of two ”hits”?.  Gastroenterology. 1998;  114 842-845
    Google Scholar
  • 31 DeLeve L D, Shulman H M, McDonald G B. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease).  Semin Liver Dis. 2002;  22 27-42
    Google Scholar
  • 32 Dufour J F, Oneta C M. Alcoholic and non-alcoholic steatohepatitis.  Ther Umsch. 2004;  61 505-512
    Google Scholar
  • 33 Duvnjak M, Lerotic I, Barsic N. et al . Pathogenesis and management issues for non-alcoholic fatty liver disease.  World J Gastroenterol. 2007;  13 4539-4550
    Google Scholar
  • 34 Edmison J, McCullough A J. Pathogenesis of non-alcoholic steatohepatitis: human data.  Clin Liver Dis. 2007;  11 75-104
    Google Scholar
  • 35 Falck-Ytter Y, Younossi Z M, Marchesini G. et al . Clinical features and natural history of nonalcoholic steatosis syndromes.  Semin Liver Dis. 2001;  21 17-26
    Google Scholar
  • 36 Farrell G C, Larter C Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis.  Hepatology. 2006;  43 S99-S112
    Google Scholar
  • 37 Friedrich-Rust M, Ong M F, Martens S. et al . Performance of transient elastography for the staging of liver fibrosis: a meta-analysis.  Gastroenterology. 2008;  134 960-974
    Google Scholar
  • 38 Gentilucci U V, Santini D, Vincenzi B. et al . Chemotherapy-induced steatohepatitis in colorectal cancer patients.  J Clin Oncol. 2006;  24 5467-5468
    Google Scholar
  • 39 Gramlich T, Kleiner D E, McCullough A J. et al . Pathologic features associated with fibrosis in nonalcoholic fatty liver disease.  Hum Pathol. 2004;  35 196-199
    Google Scholar
  • 40 Harrison S A, Torgerson S, Hayashi P H. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study.  Am J Gastroenterol. 2003;  98 2042-2047
    Google Scholar
  • 41 Hubscher S G. Role of liver biopsy in the assessment of non-alcoholic fatty liver disease.  Eur J Gastroenterol Hepatol. 2004;  16 1107-1115
    Google Scholar
  • 42 Joy D, Thava V R, Scott B B. Diagnosis of fatty liver disease: is biopsy necessary?.  Eur J Gastroenterol Hepatol. 2003;  15 539-543
    Google Scholar
  • 43 Kacerovsky M, Roden M. Nichtalkoholische Fettleber.  Diabetologe. 2007;  3 176-183
    Google Scholar
  • 44 Karoui M, Penna C, min-Hashem M. et al . Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases.  Ann Surg. 2006;  243 1-7
    Google Scholar
  • 45 Kleiner D E, Brunt E M, Van Natta M. et al . Design and validation of a histological scoring system for nonalcoholic fatty liver disease.  Hepatology. 2005;  41 1313-1321
    Google Scholar
  • 46 Lackner C, Gogg-Kamerer M, Zatloukal K. et al . Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis.  J Hepatol. 2008;  48 821-828
    Google Scholar
  • 47 Ludwig J, McGill D B, Lindor K D. Review: nonalcoholic steatohepatitis.  J Gastroenterol Hepatol. 1997;  12 398-403
    Google Scholar
  • 48 Ludwig J, Viggiano T R, McGill D B. et al . Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.  Mayo Clin Proc. 1980;  55 434-438
    Google Scholar
  • 49 Matteoni C A, Younossi Z M, Gramlich T. et al . Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.  Gastroenterology. 1999;  116 1413-1419
    Google Scholar
  • 50 Medina J, Fernandez-Salazar L I, Garcia-Buey L. et al . Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis.  Diabetes Care. 2004;  27 2057-2066
    Google Scholar
  • 51 Mendez-Sanchez N, Arrese M, Zamora-Valdes D. et al . Current concepts in the pathogenesis of nonalcoholic fatty liver disease.  Liver Int. 2007;  27 423-433
    Google Scholar
  • 52 Mendler M H, Kanel G, Govindarajan S. Proposal for a histological scoring and grading system for non-alcoholic fatty liver disease.  Liver Int. 2005;  25 294-304
    Google Scholar
  • 53 Mofrad P, Contos M J, Haque M. et al . Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values.  Hepatology. 2003;  37 1286-1292
    Google Scholar
  • 54 Moss A, Wabitsch M, Kromeyer-Hauschild K. et al . Prevalence of overweight and adiposity in German school children.  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007;  50 1424-1431
    Google Scholar
  • 55 Nakano H, Oussoultzoglou E, Rosso E. et al . Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy.  Ann Surg. 2008;  247 118-124
    Google Scholar
  • 56 Neuschwander-Tetri B A. Evolving pathophysiologic concepts in nonalcoholic steatohepatitis.  Curr Gastroenterol Rep. 2002;  4 31-36
    Google Scholar
  • 57 Neuschwander-Tetri B A, Caldwell S H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference.  Hepatology. 2003;  37 1202-1219
    Google Scholar
  • 58 Nocito A, El-Badry A M, Clavien P A. When is steatosis too much for transplantation?.  J Hepatol. 2006;  45 494-499
    Google Scholar
  • 59 Nordlinger B, Van Cutsem E, Rougier P. et al . Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group.  Eur J Cancer. 2007;  43 2037-2045
    Google Scholar
  • 60 Oneta C M, Dufour J F. Diagnostik, Prognose und therapeutische Möglichkeiten der nicht-alkoholischen Fettlebererkrankung.  Schweiz Med Forum. 2003;  37 862-868
    Google Scholar
  • 61 Papandreou D, Rousso I, Mavromichalis I. Update on non-alcoholic fatty liver disease in children.  Clin Nutr. 2007;  26 409-415
    Google Scholar
  • 62 Rashid M, Roberts E. Nonalcoholic steatohepatitis in children.  J Pediatr Gastroenterol Nutr. 2000;  30 48-53
    Google Scholar
  • 63 Ratziu V, Charlotte F, Heurtier A. et al . Sampling variability of liver biopsy in nonalcoholic fatty liver disease.  Gastroenterology. 2005;  128 1898-1906
    Google Scholar
  • 64 Reid A E. Nonalcoholic steatohepatitis.  Gastroenterology. 2001;  121 710-723
    Google Scholar
  • 65 Roberts E A. Steatohepatitis in children.  Best Pract Res Clin Gastroenterol. 2002;  16 749-765
    Google Scholar
  • 66 Roberts E A. Non-alcoholic steatohepatitis in children.  Clin Liver Dis. 2007;  11 155-72
    Google Scholar
  • 67 Rousselet M C, Michalak S, Dupre F. et al . Sources of variability in histological scoring of chronic viral hepatitis.  Hepatology. 2005;  41 257-264
    Google Scholar
  • 68 Sanyal A J, Banas C, Sargeant C. et al . Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C.  Hepatology. 2006;  43 682-689
    Google Scholar
  • 69 Schwimmer J B. Definitive diagnosis and assessment of risk for nonalcoholic fatty liver disease in children and adolescents.  Semin Liver Dis. 2007;  27 312-318
    Google Scholar
  • 70 Schwimmer J B, Behling C, Newbury R. et al . Histopathology of pediatric nonalcoholic fatty liver disease.  Hepatology. 2005;  42 641-649
    Google Scholar
  • 71 Sonsuz A, Basaranoglu M, Ozbay G. Relationship between aminotransferase levels and histopathological findings in patients with nonalcoholic steatohepatitis.  Am J Gastroenterol. 2000;  95 1370-1371
    Google Scholar
  • 72 Strassburg C P, Manns M P. Approaches to liver biopsy techniques – revisited.  Semin Liver Dis. 2006;  26 318-327
    Google Scholar
  • 73 Tannapfel A, Geissler F, Witzigmann H. et al . Analysis of liver allograft rejection related genes using cDNA-microarrays in liver allograft specimen.  Transplant Proc. 2001;  33 3283-3284
    Google Scholar
  • 74 Tannapfel A, Reinacher-Schick A. Chemotherapy associated hepatotoxicity in the treatment of advanced colorectal cancer (CRC).  Z Gastroenterol. 2008;  46 435-440
    Google Scholar
  • 75 Targher G, Bertolini L, Rodella S. et al . Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease.  Clin Endocrinol (Oxf). 2006;  64 679-683
    Google Scholar
  • 76 Teli M R, James O F, Burt A D. et al . The natural history of nonalcoholic fatty liver: a follow-up study.  Hepatology. 1995;  22 1714-1719
    Google Scholar
  • 77 Vauthey J N, Pawlik T M, Ribero D. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.  J Clin Oncol. 2006;  24 2065-2072
    Google Scholar
  • 78 Wieckowska A, McCullough A J, Feldstein A E. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future.  Hepatology. 2007;  46 582-589
    Google Scholar
  • 79 Wieckowska A, Zein N N, Yerian L M. et al . In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.  Hepatology. 2006;  44 27-33
    Google Scholar
  • 80 Younossi Z M, Jarrar M, Nugent C. et al . A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH).  Obes Surg. 2008;  18 1430-1437
    Google Scholar
  • 81 Zivkovic A M, German J B, Sanyal A J. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease.  Am J Clin Nutr. 2007;  86 285-300
    Google Scholar

Prof. Dr. Andrea Tannapfel

Institut für Pathologie, Ruhr-Universität Bochum

Bürkle-de-la-Camp Platz 1

44789 Bochum

Phone: ++ 49/2 34/3 02 48 00

Fax: ++ 49/2 34/3 02 48 09

Email: andrea.tannapfel@rub.de